The present disclosure provides LPA antagonists, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.

The present disclosure provides LPA antagonists, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.

The present invention provides a compound, and method of selectively inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, said compound having the structure:

##STR00001##

The present invention provides a compound, and method of selectively inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, said compound having the structure:

##STR00001##

Disclosed in the present invention are a compound represented by formula Ib or IIb, a cis or trans isomer, enantiomer, diastereomer, racemate, tautomer, solvate, hydrate, and pharmaceutically acceptable salt thereof, or a mixture thereof, a pharmaceutical composition containing the compound, and a use of the compound as a GPR40 agonist, wherein n, E, G.sup.1, L.sup.1, L.sup.2, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.5b, R.sup.6, R.sup.7, X.sup.5, X.sup.6, X.sup.7, Y, Y.sup.1, Z, Z.sup.1, and the possible isotopic substitution label of each element in the compound are as defined in the description.

##STR00001##

Disclosed in the present invention are a compound represented by formula Ib or IIb, a cis or trans isomer, enantiomer, diastereomer, racemate, tautomer, solvate, hydrate, and pharmaceutically acceptable salt thereof, or a mixture thereof, a pharmaceutical composition containing the compound, and a use of the compound as a GPR40 agonist, wherein n, E, G.sup.1, L.sup.1, L.sup.2, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.5b, R.sup.6, R.sup.7, X.sup.5, X.sup.6, X.sup.7, Y, Y.sup.1, Z, Z.sup.1, and the possible isotopic substitution label of each element in the compound are as defined in the description.

##STR00001##

The present disclosure provides a process for preparing an aryl ketone of Formula I, comprising reacting a substituted benzene of Formula II with a carboxylic acid of formula IIIa and/or a carboxylic anhydride of formula IIIb in presence of an alkyl sulfonic acid acting as catalyst cum solvent/contacting medium. I, II, IIIa, IIIb, wherein, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined in the description. ##STR00001##

The present invention provides an improved process for preparation of L-threo-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) (Droxidopa) and its salts; comprising (a) reaction of the aldehyde compound (III) (as described herein) with Metal complex (II) (as described herein), and (h) hydrolysis of the compound (IV) obtained from step (a) in presence of acid. The present invention also relates to a novel intermediates metal chiral complex (IV) for the preparation of Droxidopa.

This disclosure relates to aryl amidines of Formula I and their use as fungicides.

##STR00001##

This disclosure relates to aryl amidines of Formula I and their use as fungicides.

##STR00001##